Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation

This is a single-center, open-label, randomized, single dose, 3-way crossover study in healthy volunteers designed to evaluate the relative bioavailability of a new oral tablet formulation of linaprazan glurate in comparison to a previously studied oral tablet formulation under fasting conditions, and to assess the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of linaprazan glurate and the active substance linaprazan after the administration of the new oral tablet formulation.

Main Inclusion Criteria:Willing and able to give written informed consent for participation in the study.Healthy male or female aged 18 to 65 years, inclusive.Body mass index ≥18.5 and ≤30.0 kg/m2.Medically healthy, without abnormal clinically significant medical historyFemale subjects of childbearing potential, as well as their partners and male subjects and their partners, who agree to using methods of contraceptionWilling and able to consume the high-fat, high calorie breakfastExclusion Criteria:Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of <1%) from 2 weeks prior to dosing until the end-of-study visit.Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocolHistory of or current clinically significant disease as defined in the protocol.History of GERD, significant acid reflux.Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit).